Publications dans lesquelles il/elle collabore avec Jesús María Prieto Valtueña (204)

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Identifying differentially expressed micrornas, target genes, and key pathways deregulated in patients with liver diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-16

2019

  1. La clínica y el laboratorio: interpretación de análisis y pruebas funcionales, exploración de los síndromes, cuadro biológico de las enfermedades

    Elsevier

  2. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905

  3. The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells

    Cell Death and Disease, Vol. 10, Núm. 1

2017

  1. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828

  2. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

  3. X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse Liver

    Gastroenterology, Vol. 152, Núm. 5, pp. 1203-1216.e15

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Insulin-like growth factor I (IGF-I) expressed from an AAV1 vector leads to a complete reversion of liver cirrhosis in rats

    PLoS ONE, Vol. 11, Núm. 9

  3. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

  4. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression

    Oncogene, Vol. 35, Núm. 36, pp. 4719-4729

  5. Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis

    Journal of Immunology, Vol. 197, Núm. 6, pp. 2145-2156

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. La clínica y el laboratorio: interpretación de análisis y pruebas funcionales, exploración de los síndromes, cuadro biológico de las enfermedades

    Elsevier Masson

  3. Matrix Metalloproteinase 10 Contributes To Hepatocarcinogenesis in a Novel Crosstalk With the Stromal Derived Factor 1/C-X-C Chemokine Receptor 4 Axis

    Hepatology, Vol. 62, Núm. 1, pp. 166-178

2014

  1. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation

    Journal of Hepatology, Vol. 60, Núm. 5, pp. 1017-1025

  2. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  3. Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair

    Liver International, Vol. 34, Núm. 7

  4. Splicing regulator SLU7 is essential for maintaining liver homeostasis

    Journal of Clinical Investigation, Vol. 124, Núm. 7, pp. 2909-2920